Why Teleflex (TFX) Stock Is Up Today

Teleflex (TFX) is up 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a fresh analyst upgrade that turned more bullish on Teleflex’s earnings setup and execution under management. The move may also be getting support from the company’s recently completed OEM divestiture, which improved balance-sheet flexibility and set up larger buybacks and debt reduction.

Details:

An analyst note published Monday upgraded Teleflex to Buy from Neutral and raised the price target to $158 from $145, signaling improved confidence in upside potential.

Teleflex completed the sale of its OEM business in August for $1.5 billion in cash, a major portfolio step that leaves the company more focused on its remaining medical technology businesses.

The company has said the OEM sale proceeds are intended to support about $800 million of debt paydown and the completion of a $1 billion share repurchase authorization, which can be supportive for equity valuation.

Teleflex’s recent filings and investor materials continue to frame 2026 as a transition year, with 2027 expected to better reflect the earnings power of the slimmer post-divestiture business.

Sources:

SEC, Teleflex Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive TFX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$TFX Hedge Fund Activity

We have seen 193 institutional investors add shares of $TFX stock to their portfolio, and 257 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CITADEL ADVISORS LLC added 1,105,534 shares (+1686.2%) to their portfolio in Q1 2026, for an estimated $132,232,921
MILLENNIUM MANAGEMENT LLC added 760,045 shares (+111.4%) to their portfolio in Q2 2026, for an estimated $96,343,304
GOLDMAN SACHS GROUP INC added 707,189 shares (+356.1%) to their portfolio in Q2 2026, for an estimated $89,643,277
POINT72 ASSET MANAGEMENT, L.P. removed 677,308 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $85,855,562
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 534,218 shares (+inf%) to their portfolio in Q2 2026, for an estimated $67,717,473
HOLOCENE ADVISORS, LP added 470,946 shares (+113.4%) to their portfolio in Q2 2026, for an estimated $59,697,114
INVESCO LTD. added 438,868 shares (+325.0%) to their portfolio in Q2 2026, for an estimated $55,630,907

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$TFX Government Contracts

We have seen $204,453 of award payments to $TFX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

AORTIC BALLOON PUMPS: $65,020
RATIFICATION: $18,900
HELIUM REGULATOR PM: $15,990

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$TFX Price Targets

Multiple analysts have issued price targets for $TFX recently. We have seen 5 analysts offer price targets for $TFX in the last 6 months, with a median target of $155.0.

Here are some recent targets:

Vik Chopra from BMO Capital set a target price of $159.0 on 07/09/2026
Matt O'Brien from Piper Sandler set a target price of $160.0 on 06/08/2026
Ravi Misra from Truist Securities set a target price of $143.0 on 05/11/2026
Larry Biegelsen from Wells Fargo set a target price of $138.0 on 05/08/2026
Shagun Singh from RBC Capital set a target price of $155.0 on 05/08/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.